Business Context and Reporting Period
This Form 8-K Current Report is filed by PharmAthene, Inc. (not Altimmune, Inc.) for the reporting period of July 20, 2010. The company is a Delaware corporation focused on the development of vaccines, specifically the SparVaxTM second-generation anthrax vaccine program, with significant contracts involving U.S. Government agencies such as BARDA.
Key Financial Metrics and Transaction Details
- Capital Raise: The Company entered into a Securities Purchase Agreement to sell 2,785,714 shares of common stock at $1.40 per share and warrants to purchase up to 1,323,214 additional shares.
- Gross Proceeds: Approximately $3.9 million is expected before placement agent fees and expenses.
- Transaction Costs: Placement fees are estimated at $273,000 (7.0% of gross proceeds), less a $20,475 financial advisory fee to Noble Financial Group, Inc. The Company will also reimburse expenses up to $45,000.
- Accounts Receivable: As of March 31, 2010, accounts receivable and other receivables totaled approximately $16.9 million.
- Warrant Terms: Warrants are exercisable beginning six months after issuance at an exercise price of $1.63 per share, expiring six years after the initial exercise date.
Material Changes and Operational Status
The filing highlights a material change in the Company's liquidity position driven by operational delays. A significant portion of the $16.9 million in receivables remains uncollected due to billing delays for the SparVaxTM program and normal government payment cycles. Additionally, a bid protest filed in March 2010 by a third party resulted in a "stop-work" order, which was canceled in June 2010 after the protest was denied. These factors have reduced revenues and operating cash flows, necessitating the current financing to fund working capital needs.
Outlook, Risks, and Management Commentary
- Contract Performance Risk: BARDA has expressed concerns regarding the Company's performance under its existing contract from April 1, 2009, through April 30, 2010. Management states it is working to resolve these issues but acknowledges that failure to perform adequately could lead to contract curtailment or termination.
- Liquidity Needs: The combination of billing delays and the previous stop-work order has reduced available cash, making the $3.9 million offering critical for funding operations.
- Regulatory Context: The offering is conducted pursuant to a prospectus supplement filed under Rule 424(b) as part of a shelf takedown from a Form S-3 registration statement declared effective in February 2009.
Key Facts for Investor Verification
- Verify the status of the $16.9 million in accounts receivable and the timeline for collection from U.S. Government customers.
- Confirm the resolution of performance concerns raised by BARDA regarding the SparVaxTM contract to assess the risk of termination.
- Review the full terms of the Placement Agency Agreement and Securities Purchase Agreement (Exhibits 1.1 and 10.1) for covenants and conditions.
- Monitor the Company's cash burn rate post-financing to ensure the $3.9 million proceeds are sufficient to cover working capital needs until revenue stabilizes.